Hypereosinophilic Syndrome research hub

A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)

This study looks at a new drug called benralizumab for Hypereosinophilic Syndrome (HES) in people aged 12 and over. It compares benralizumab to a dummy drug to see if it's safe and helps reduce HES symptoms.

Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial

This 52-week study is testing a new drug, depemokimab, for adults with uncontrolled Hypereosinophilic Syndrome (HES). It aims to see if depemokimab is effective and safe compared to a placebo, alongside their usual HES treatment.

Expanded access program for mepolizumab in subjects with hypereosinophilic syndrome.